Related references
Note: Only part of the references are listed.Multi-omic machine learning predictor of breast cancer therapy response
Stephen-John Sammut et al.
NATURE (2022)
Multi-omic machine learning predictor of breast cancer therapy response
Stephen-John Sammut et al.
NATURE (2022)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Oncogene-regulated release of extracellular vesicles
Seda Kilinc et al.
DEVELOPMENTAL CELL (2021)
MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
Si-Yu Wu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
Zhimei Zhou et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)
The nf-core framework for community-curated bioinformatics pipelines
Philip A. Ewels et al.
NATURE BIOTECHNOLOGY (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Jing Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Davis Y. Torrejon et al.
CANCER DISCOVERY (2020)
Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma
Nathiya Muthalagu et al.
CANCER DISCOVERY (2020)
MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities
Julia Rohrberg et al.
CELL REPORTS (2020)
Immune Escape during Breast Tumor Progression
Carlos R. Gil Del Alcazar et al.
CANCER IMMUNOLOGY RESEARCH (2020)
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
Annelisa M. Cornel et al.
CANCERS (2020)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
Marian L. Burr et al.
CANCER CELL (2019)
Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
Shixiang Wang et al.
ELIFE (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Max D. Wellenstein et al.
IMMUNITY (2018)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao et al.
SCIENCE (2018)
Eradication of spontaneous malignancy by local immunotherapy
Idit Sagiv-Barfi et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Franz X. Schaub et al.
CELL SYSTEMS (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
NATURE MEDICINE (2018)
The hallmarks of successful anticancer immunotherapy
Lorenzo Galluzzi et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
Pornpimol Charoentong et al.
CELL REPORTS (2017)
Gene expression markers of Tumor Infiltrating Leukocytes
Patrick Danaher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Roderik M. Kortlever et al.
CELL (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Michael J. Topper et al.
CELL (2017)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson et al.
CELL (2017)
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
Kyung-Min Lee et al.
CELL METABOLISM (2017)
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Sherene Loi et al.
CLINICAL CANCER RESEARCH (2016)
Identification of MYC-Dependent Transcriptional Programs in Oncogene-Addicted Liver Tumors
Theresia R. Kress et al.
CANCER RESEARCH (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Giovanni Ciriello et al.
CELL (2015)
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
Devon A. Lawson et al.
NATURE (2015)
NLRC5 Exclusively Transactivates MHC Class I and Related Genes through a Distinctive SXY Module
Kristina Ludigs et al.
PLOS GENETICS (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Linking Tumor Mutations to Drug Responses via a Quantitative Chemical-Genetic Interaction Map
Maria M. Martins et al.
CANCER DISCOVERY (2015)
Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Justin M. Balko et al.
CANCER DISCOVERY (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
The Ratios of CD8+ T Cells to CD4+ CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer
Claudia C. Preston et al.
PLOS ONE (2013)
Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts
Adam D. Pfefferle et al.
GENOME BIOLOGY (2013)
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Dai Horiuchi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
NLR family member NLRC5 is a transcriptional regulator of MHC class I genes
Torsten B. Meissner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response
Sanjay Chandriani et al.
PLOS ONE (2009)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Immunotherapeutic uses of CpG oligodeoxynucleotides
DM Klinman
NATURE REVIEWS IMMUNOLOGY (2004)
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
C Sotiriou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The role of apoptosis in creating and maintaining luminal space with normal and oncogene-expressing mammary acini
J Debnath et al.
CELL (2002)
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations
CM D'Cruz et al.
NATURE MEDICINE (2001)
Share Paper
